This fascinating development was underscored in a notable discourse in the scientific community, where the authors of the initial paper on SMPDL3B responded to a commentary addressing their claims. The central tenet of their response was to reinforce the premise that SMPDL3B is not only a potential biomarker but could also serve as a therapeutic target for ME, a condition that affects millions worldwide and remains poorly understood.

The complexity of ME is matched by the diversity of its symptoms, encompassing profound fatigue, post-exertional malaise, and cognitive disturbances. Consequently, finding reliable biomarkers is crucial for diagnosing the condition more reliably and objectively. The recent investigations into SMPDL3B aim to bridge this gap. In their initial publication, the authors meticulously outlined the biochemical properties of SMPDL3B, explaining how alterations in its level could correlate with disease status in patients with ME.

The scientific community has long sought detailed investigative avenues into the molecular underpinnings of ME. The primary significance of SMPDL3B comes from its involvement with purinergic signaling pathways, which play critical roles in energy metabolism and neuronal signaling. Abnormalities in these pathways could hence reasonably explain some of the clinical symptoms observed in ME. Through assaying the levels of SMPDL3B in patient samples, researchers hope to provide a clearer diagnostic picture and potentially implement targeted therapies that restore normal signaling functions.

Furthermore, the authors delved deeply into the biochemical action of SMPDL3B, highlighting its role in the metabolism of sphingosine 1-phosphate, a lipid mediator essential for cellular proliferation and survival. The disruption in this metabolic pathway could contribute to the pathophysiology of various diseases, including ME. Their argument firmly establishes the plausibility of SMPDL3B as a crucial player deserving further scrutiny.

In addressing the commentary on their published work, the authors articulated their confidence in their analytical methodologies, reassuring the scientific community about their rigorous research design and execution. They maintained that their findings were thoroughly validated, underscoring the importance of SMPDL3B as both a research subject and a potential clinical entity. However, the authors did not shy away from acknowledging that further research is essential to establish concrete links and therapeutic viability.

The authors’ response serves as a robust affirmation of their original claims while encouraging ongoing dialogue within the scientific field. They reiterated that their findings could catalyze further studies, thereby enriching the pool of knowledge regarding ME and elucidating the various pathways involved. Crucially, they emphasized the need for collaborative research efforts to confirm these findings and expand on them.

Despite the ongoing debate, the response underscores a pivotal turning point for SMPDL3B in ME research. Whether viewed as a biomarker, a target for therapies, or both, it encapsulates the hope that innovative approaches to diagnosis and treatment can stem from a better understanding of the molecular mechanisms at play. Researchers have the potential to turn the tide on a condition that has long eluded effective interventions.

Moreover, the implications of successful research on SMPDL3B reach beyond ME itself. The methodologies and insights gained could readily apply to other chronic illnesses sharing overlapping pathophysiological characteristics. By establishing a more integrated understanding of these mechanisms, the scientific community stands to revolutionize treatment paradigms not only for ME but for an array of complex diseases.

As the authors continue to advocate for SMPDL3B’s potential, they emphasize the importance of disseminating knowledge and findings effectively. Engaging the scientific community in an open dialogue serves as a critical catalyst for refinement and validation of ongoing research. Their efforts reflect a commitment to the broader objective of addressing unmet medical needs in patient populations suffering from ME and comparable disorders.

In conclusion, the response from the authors signifies a crucial step towards amplifying awareness about SMPDL3B as a novel biomarker and therapeutic target within the challenging landscape of myalgic encephalomyelitis research. By shedding light on the nuances of their work, they reiterate the significance of innovative research for pioneering new pathways in understanding diseases. This project, steeped in meticulous research, is poised to characterize, unveil, and hopefully mitigate the debilitating effects of ME, setting a precedent for future advancements in chronic disease management. The commitment to addressing criticisms head-on adds a vital layer of credibility to their work, paving the way for future exploration of SMPDL3B’s role in the medical field.

Through this discourse, researchers amplify the hope that collaborative efforts will unveil novel therapeutic avenues for myalgic encephalomyelitis, spanning biomarker identification to targeted treatments. Such pioneering research may also incentivize broader conversations about similar pathways in other chronic illnesses, ultimately forging a more profound understanding of biological complexities. In due course, this may lead to innovative solutions that facilitate improved patient care, underscoring the inherent value of rigorous scientific inquiry.

In a world perpetually striving for progress in medical sciences, the journey of identifying and validating SMPDL3B acts as an emblem of hope for many afflicted by ME and similar chronic conditions. The compelling evidence and ongoing discourse promoted by the authors will undoubtedly resonate through future scientific endeavors, shaping the conversation around ME and the associated molecular mechanisms that guide therapy development.

With this article, the authors not only present a case for SMPDL3B’s clinical relevance but also invite ethical and collaborative approaches to research. Their open dialogue emphasizes the ongoing evolution of understanding and highlights the necessity for robust evidence in medical sciences. This aligns with broader calls in the scientific community for accountability, clarity, and engagement across disciplines as we tackle the complexities of human health together.

Possibly, the exploration of SMPDL3B could soon usher in an era where diagnostic and therapeutic breakthroughs become tangible realities for those navigating the multifaceted journey of myalgic encephalomyelitis.

Subject of Research: Myalgic Encephalomyelitis and SMPDL3B as a Biomarker and Therapeutic Target

Article Title: Authors’ Response to “Comment on ‘SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis’”

Article References: Rostami-Afshari, B., Elremaly, W., Franco, A. et al. Authors’ Response to “Comment on ‘SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis’”. J Transl Med 24, 75 (2026). https://doi.org/10.1186/s12967-025-07583-z

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07583-z

Keywords: Myalgic Encephalomyelitis, SMPDL3B, Biomarkers, Therapeutic Targets, Chronic Illness, Research, Molecular Mechanisms

ME/CFS, characterized by profound and persistent fatigue not alleviated by rest, significantly impairs quality of life. Despite its prevalence, including over 400,000 known cases in the United Kingdom alone, the condition has remained poorly understood in clinical settings due to the absence of definitive diagnostic markers. Patients frequently report skepticism from healthcare professionals and delays in receiving appropriate care, exacerbating the burden of this chronic illness.

Professor Dmitry Pshezhetskiy from UEA’s Norwich Medical School, who led the study, emphasized the pressing need for objective diagnostic tools. He explained that the new test could fundamentally alter the clinical approach to ME/CFS by providing a tangible biomarker for diagnosis. Early and accurate identification could enable timely interventions, personalized management strategies, and reduce the psychological toll on patients who are often stigmatized or dismissed.

The innovative blood test leverages Oxford BioDynamics’ proprietary EpiSwitch® 3D Genomics platform. This advanced technology interrogates the three-dimensional folding patterns of DNA within blood cells. While our genetic code is linear and fixed, the spatial configuration of the genome—the epigenome—modulates gene activity dynamically, responding to environmental and physiological cues. By analyzing these complex 3D genomic structures, researchers can identify epigenetic markers indicative of disease states.

In this study, blood samples from 47 individuals diagnosed with severe ME/CFS and 61 healthy controls were subjected to comprehensive EpiSwitch® analysis. This approach revealed distinctive and reproducible DNA folding signatures exclusive to ME/CFS patients, forming the basis for the test’s diagnostic criteria. The epigenetic markers identified are not embedded in the genetic code itself but reflect regulatory changes that influence immune function and inflammatory pathways implicated in ME/CFS pathology.

Alexandre Akoulitchev, Chief Scientific Officer at Oxford BioDynamics, highlighted that ME/CFS is fundamentally an acquired condition rather than a congenital genetic disorder. Therefore, detecting dynamic epigenetic changes is superior to traditional genetic screening for diagnosis. The EpiSwitch® platform’s capability to dissect precise 3D genomic alterations enables rapid and scalable diagnostic assessments, distinguishing it from other blood test modalities.

Significantly, the test demonstrated 92 percent sensitivity, meaning it reliably identified individuals with ME/CFS, and an impressive 98 percent specificity, effectively excluding individuals without the disease. This high degree of accuracy surpasses existing diagnostic methods, which rely heavily on symptom-based criteria and often lead to false positives or negatives. Such precision paves the way for confident clinical decision-making and personalized patient management.

Beyond diagnostic utility, the analysis unearthed molecular insights into the biological pathways active in ME/CFS. The researchers pinpointed disruptions in immune system regulation and chronic inflammatory responses, consistent with the hypothesized immunological underpinnings of the illness. These findings not only enhance understanding of ME/CFS but also suggest potential targets for therapeutic intervention and patient stratification according to molecular profiles.

The implications of this research extend into the emergent field of post-viral syndromes, particularly long Covid. ME/CFS-like symptom clusters have been observed following SARS-CoV-2 infection, often termed post-Covid syndrome. The researchers propose that the EpiSwitch® test framework could be adapted to detect similar epigenetic signatures in long Covid patients, facilitating early diagnosis and tailored treatment approaches in this expanding clinical challenge.

Historically, Oxford BioDynamics’ EpiSwitch® technology has proven successful in identifying disease-specific biomarkers in other complex conditions, including rapidly progressing neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), autoimmune diseases like rheumatoid arthritis, and various cancers. Notably, the EpiSwitch® PSE test for prostate cancer has already achieved global recognition for its diagnostic accuracy, underscoring the platform’s broad applicability and clinical impact.

This breakthrough represents a paradigm shift in ME/CFS research and clinical practice, transcending traditional genetic analyses such as the DecodeME initiative. While DecodeME focused on linear genomic sequencing to uncover hereditary risk loci, the current work pioneers a complementary approach by mapping dynamic 3D genomic structures, uncovering hundreds of additional disease-associated changes. This integrated genomic and epigenomic perspective promises more comprehensive disease characterization.

The study’s authors advocate for the integration of the EpiSwitch® CFS blood test into routine clinical diagnostic protocols for ME/CFS, offering a tool that is both practical and scalable within healthcare systems. This advance is poised to reduce diagnostic delays, increase patient validation, and foster development of targeted therapeutics, heralding a new era in the management of this challenging chronic disease.

Published in the esteemed Journal of Translational Medicine, this research exemplifies the power of cutting-edge genomic technologies to unravel complex disease mechanisms and translate bench-side discoveries into clinical innovations. It signals hope to millions grappling with ME/CFS and lays foundational work towards addressing the diagnostic voids that have long confounded patients and clinicians alike.

The research was a concerted effort by UEA, Oxford BioDynamics, the London School of Hygiene & Tropical Medicine, and the Royal Cornwall Hospitals NHS Trust. Their collective expertise and technological innovation have delivered a much-needed, objective diagnostic instrument that promises to transform patient outcomes and stimulate further investigation into the molecular biology of ME/CFS and long Covid.

Subject of Research: Human tissue samples
Article Title: ‘Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling’
News Publication Date: 8-Oct-2025
Web References: https://www.94percent.com/
References: DecodeME genetic study on ME/CFS
Keywords: COVID 19, Diseases and disorders, Clinical medicine, Medical diagnosis, Medical tests